Rick Doblin on the FDA's MDMA Decision and the Future of Psychedelic Therapy
Timely insights from Rick Doblin on the FDA's decision on MDMA and its impact on psychedelic research and therapy in 2025.
Webinar
-
-
Description
-
Video Recording of Conversation with Rick Doblin
-
.png)
About this course
- Free
- 1.5 hours of video content
Start your learning journey
Additional products
-
School of Psychedelics Annual Membership
Bundle • 24 learning productsGet unlimited access to all our premium content for a full year. Enjoy exclusive resources, new releases, and priority support. Learn anytime, anywhere, and advance your skills with our comprehensive library. Join today and start your journey!
$500 / year
-
Psychedelics in Canada: Past, Present and Future
Bundle • 8 learning productsExperience the full spectrum of psychedelic knowledge with our complete seminar series. These seven insightful courses cover everything from the historical roots to the modern applications of psychedelics.
$275
-
Cannabis and Psychedelics: From Conceptualization to Care in Canada
Bundle • 7 learning productsThis course considers the similarities and differences between cannabis and psychedelics, exploring whether cannabis is a psychedelic substance, why that matters, and to whom.
$250
